Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

pharmafile | June 26, 2019 | News story | Manufacturing and Production, Medical Communications, Sales and Marketing Shire, Takeda, US, pharma 

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of the year – a hard date was given of 31 December – with the aim of selling the 777,000-square-foot campus by 31 March 2020.

This is not an insignificant task, as the site currently employs around 1,000 workers. The strategy will see some of this workforce working remotely, while some will be moved to a transitional location, according to Takeda spokesperson Julia Ellwanger. She highlighted Shire’s former offices in Bannockburn as a transitional site, but she did not confirm how many staff would be operating there or for how long.

“Integration activities with respect to certain groups that currently reside in Deerfield are ongoing, and we are encouraged by the progress we have made thus far,” Ellwanger commented. “Managers and their teams are working to consider employee needs and the needs of the business. Where possible, roles have been designated as remote or field based, while others require co-location due to the nature of the work.

“In cases where there isn’t a solution that meets the business and/or an employee’s needs, the employee will be provided with severance and transition support programmes,” she added.

Though the Japanese firm first announced its plans to sell the site back in September last year, it was not made clear how many employees would be affected. The decision ends the company’s presence in the state after 40 years, as it moves to consolidate its US operations in Massachusetts following its acquisition of Irish pharma firm Shire.

Matt Fellows

Related Content

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content